๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Primary Central Nervous System Lymphoma
Clinical trial register · China

Primary Central Nervous System Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Guangzhou 2 Zhengzhou 2 Nanjing 2 Hanzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Guangzhou2 Zhengzhou2 Nanjing2 Hanzhou1
All 19 locations
Target enrolment
to

Primary Central Nervous System Lymphoma trials in China

10 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
NCT07350850PCNSL, Primary Central Nervous System Lymphoma
Tongji Hospital
Phase 2
77
Xiamen, Wuhan, Changchun, Taiyuan
2025-12-25
Recruiting
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT07185373Primary Central Nervous System Lymphoma
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Recruiting
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NCT06832267Primary Central Nervous System Lymphoma
Zhejiang Cancer Hospital
Not applicable
44
Hangzhou
2025-02-14
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
NCT05485753Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
7
Beijing, Guangzhou, Zhengzhou
2023-02-10
Recruiting
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT05600660Primary Central Nervous System Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
28
Hanzhou
2022-08-01
Recruiting
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
NCT04737889Primary Central Nervous System Lymphoma
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2021-01-13
Recruiting
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
NCT04070040Primary Central Nervous System Lymphoma
Beijing Sanbo Brain Hospital
Phase 2
21
Beijing
2020-02-13
Recruiting
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
NCT02836158Primary Central Nervous System Lymphoma
Navy General Hospital, Beijing
Phase 2/3
100
Beijing
2010-09
Recruiting
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
NCT02657785Primary Central Nervous System Lymphoma
Navy General Hospital, Beijing
Phase 2/3
100
Beijing
2010-09
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/primary-central-nervous-system-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Primary Central Nervous System Lymphoma.

How many Primary Central Nervous System Lymphoma trials are recruiting in China?

8 of the 10 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Primary Central Nervous System Lymphoma), 10 studies
PhaseStudiesRecruitingShare
Phase 24440%
Phase 2/33330%
Not applicable2120%
Phase 1/21010%

Most active sponsors

Lead sponsors with the most studies (Primary Central Nervous System Lymphoma)
Lead sponsorStudiesRecruiting
Navy General Hospital, Beijing22
Beijing Sanbo Brain Hospital11
Henan Cancer Hospital11
Huashan Hospital11
Second Affiliated Hospital, Zhejiang University, School of Medicine11
Sichuan Baili Pharmaceutical Co., Ltd.10
Tongji Hospital11
WEI XU10
Zhejiang Cancer Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.